Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ITK | Q08881 | 5/20 | 0.61 |
| ▸ | KDR | P35968 | 5/20 | 0.60 |
| ▸ | FLT1 | P17948 | 3/20 | 0.60 |
| ▸ | TEK | Q02763 | 3/20 | 0.60 |
| ▸ | AURKA | O14965 | 3/20 | 0.60 |
| ▸ | AURKB | Q96GD4 | 3/20 | 0.60 |
| ▸ | RET | P07949 | 3/20 | 0.60 |
| ▸ | KIT | P10721 | 2/20 | 0.60 |
| ▸ | DCLK1 | O15075 | 1/20 | 0.60 |
| ▸ | DYRK3 | O43781 | 1/20 | 0.60 |
| ▸ | ROCK2 | O75116 | 1/20 | 0.60 |
| ▸ | MAP4K4 | O95819 | 1/20 | 0.60 |
| ▸ | CHEK2 | O96017 | 1/20 | 0.60 |
| ▸ | NTRK1 | P04629 | 1/20 | 0.60 |
| ▸ | LCK | P06239 | 1/20 | 0.60 |
| ▸ | CDK1 | P06493 | 1/20 | 0.60 |
| ▸ | LYN | P07948 | 1/20 | 0.60 |
| ▸ | ROS1 | P08922 | 1/20 | 0.60 |
| ▸ | FGFR1 | P11362 | 1/20 | 0.60 |
| ▸ | RPS6KB1 | P23443 | 1/20 | 0.60 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1320309 | 0.90 | KDR (0.57) | ITKKDRFLT1TEKAURKA | |
| SCHEMBL1321162 | 0.90 | KDR (0.57) | ITKKDRFLT1TEKAURKA | |
| SCHEMBL1320312 | 0.90 | KDR (0.57) | ITKKDRFLT1TEKAURKA | |
| SCHEMBL1319544 | 0.90 | KDR (0.58) | ITKKDRFLT1TEKAURKA | |
| SCHEMBL1317675 | 0.90 | KDR (0.58) | ITKKDRFLT1TEKAURKA | |
| SCHEMBL1317672 | 0.90 | KDR (0.58) | ITKKDRFLT1TEKAURKA | |
| SCHEMBL1318164 | 0.88 | ITK (0.61) | ITKKDRFLT1TEKAURKA | |
| SCHEMBL1318165 | 0.88 | ITK (0.61) | ITKKDRFLT1TEKAURKA | |
| SCHEMBL1320259 | 0.88 | ITK (0.61) | ITKKDRFLT1TEKAURKA | |
| SCHEMBL12120719 | 0.87 | AURKB (0.73) | KDRFLT1TEKAURKAAURKB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2358720-B1 | FUSED RING HETEROARYL KINASE INHIBITORS | UNIV CALIFORNIA (US) | 2016-03-02 | — | — | EP | disclosed |
| EP-2358720-B1 | FUSED RING HETEROARYL KINASE INHIBITORS | UNIV CALIFORNIA (US) | 2016-03-02 | — | — | EP | disclosed |
| US-8980899-B2 | Methods of inhibiting Ire1 | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2015-03-17 | — | — | US | disclosed |
| US-8980899-B2 | Methods of inhibiting Ire1 | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2015-03-17 | — | — | US | disclosed |
| US-8980899-B2 | Methods of inhibiting Ire1 | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2015-03-17 | — | — | US | disclosed |
| US-8697709-B2 | Fused ring heteroaryl kinase inhibitors | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2014-04-15 | — | — | US | disclosed |
| US-20120322814-A1 | METHODS OF INHIBITING IRE1 | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2012-12-20 | — | — | US | disclosed |
| US-20120322814-A1 | METHODS OF INHIBITING IRE1 | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2012-12-20 | — | — | US | disclosed |
| US-20120322814-A1 | METHODS OF INHIBITING IRE1 | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2012-12-20 | — | — | US | disclosed |
| US-20110275651-A1 | FUSED RING HETEROARYL KINASE INHIBITORS | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2011-11-10 | — | — | US | disclosed |
| US-20110275651-A1 | FUSED RING HETEROARYL KINASE INHIBITORS | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2011-11-10 | — | — | US | disclosed |
| US-20110275651-A1 | FUSED RING HETEROARYL KINASE INHIBITORS | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2011-11-10 | — | — | US | disclosed |
| EP-2358720-A2 | FUSED RING HETEROARYL KINASE INHIBITORS | The Regents of the University of California (US) | 2011-08-24 | — | — | EP | disclosed |
| WO-2011047384-A2 | METHODS OF INHIBITING IRE1 | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2011-04-21 | — | — | WO | disclosed |
| WO-2010045542-A2 | FUSED RING HETEROARYL KINASE INHIBITORS | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2010-04-22 | — | — | WO | disclosed |
| WO-2010045542-A2 | FUSED RING HETEROARYL KINASE INHIBITORS | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2010-04-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120322814-A1 | METHODS OF INHIBITING IRE1 | XBP1, DNAJC10, HSPA5 | ITK 4490/4885KDR 4859/4885FLT1 4868/4885 |
| US-20110275651-A1 | FUSED RING HETEROARYL KINASE INHIBITORS | CNKSR1, MAP3K20, TTK | ITK 735/4885KDR 837/4885FLT1 1283/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.